SG Americas Securities LLC Lowers Stake in Vericel Co. (NASDAQ:VCEL)

SG Americas Securities LLC lowered its stake in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 36.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,405 shares of the biotechnology company's stock after selling 23,659 shares during the period. SG Americas Securities LLC owned about 0.08% of Vericel worth $1,439,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. BlackRock Inc. boosted its position in Vericel by 2.7% during the second quarter. BlackRock Inc. now owns 7,632,598 shares of the biotechnology company's stock worth $286,757,000 after acquiring an additional 201,157 shares during the last quarter. State Street Corp boosted its position in Vericel by 15.6% during the second quarter. State Street Corp now owns 3,400,735 shares of the biotechnology company's stock worth $85,631,000 after acquiring an additional 458,219 shares during the last quarter. Vanguard Group Inc. boosted its position in Vericel by 2.8% during the third quarter. Vanguard Group Inc. now owns 3,234,095 shares of the biotechnology company's stock worth $75,031,000 after acquiring an additional 88,923 shares during the last quarter. Morgan Stanley boosted its position in Vericel by 104.2% during the third quarter. Morgan Stanley now owns 1,356,426 shares of the biotechnology company's stock worth $45,467,000 after acquiring an additional 692,260 shares during the last quarter. Finally, Macquarie Group Ltd. boosted its position in Vericel by 7.3% during the first quarter. Macquarie Group Ltd. now owns 1,144,076 shares of the biotechnology company's stock worth $33,544,000 after acquiring an additional 78,158 shares during the last quarter.

Insider Transactions at Vericel

In other news, CEO Dominick Colangelo sold 16,726 shares of the company's stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $38.58, for a total value of $645,289.08. Following the transaction, the chief executive officer now directly owns 169,985 shares in the company, valued at approximately $6,558,021.30. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Dominick Colangelo sold 16,726 shares of the company's stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $38.58, for a total value of $645,289.08. Following the transaction, the chief executive officer now directly owns 169,985 shares in the company, valued at approximately $6,558,021.30. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,200 shares of the company's stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $38.09, for a total transaction of $83,798.00. Following the sale, the director now directly owns 30,895 shares in the company, valued at $1,176,790.55. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,193 shares of company stock worth $2,845,068. 5.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on VCEL shares. HC Wainwright boosted their price target on shares of Vericel from $46.00 to $53.00 and gave the stock a "buy" rating in a research report on Friday, March 1st. Truist Financial restated a "buy" rating and set a $54.00 price target on shares of Vericel in a research report on Tuesday. Finally, TheStreet upgraded shares of Vericel from a "d+" rating to a "c-" rating in a research report on Monday, January 29th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Vericel currently has a consensus rating of "Moderate Buy" and an average price target of $46.40.

Vericel Stock Down 0.6 %

NASDAQ:VCEL traded down $0.31 on Friday, hitting $52.02. The stock had a trading volume of 473,847 shares, compared to its average volume of 505,550. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of -577.94 and a beta of 1.69. The company has a fifty day moving average price of $45.97 and a two-hundred day moving average price of $38.86. Vericel Co. has a 1-year low of $28.02 and a 1-year high of $52.50.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The biotechnology company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.18 by $0.08. Vericel had a negative net margin of 1.61% and a negative return on equity of 1.55%. The firm had revenue of $65.00 million for the quarter, compared to analyst estimates of $64.28 million. During the same period in the prior year, the business posted $0.12 EPS. The business's revenue for the quarter was up 23.3% compared to the same quarter last year. As a group, analysts anticipate that Vericel Co. will post 0.09 earnings per share for the current year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.